Pediatric ependymoma

Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to arise from radial glial cells lining the ventricular system. However, they differ from adult ependymomas in which genes and chromosomes are most often affected, the region of the brain they are most frequently found in, and the prognosis of the patients. Children with certain hereditary diseases, such as neurofibromatosis type II (NF2), have been found to be more frequently afflicted with this class of tumors, but a firm genetic link remains to be established. Symptoms associated with the development of pediatric ependymomas are varied, much like symptoms for a number of other pediatric brain tumors including vomiting, headache, irritability, lethargy, and changes in gait. Although younger children and children with invasive tumor types generally experience less favorable outcomes, total removal of the tumors is the most conspicuous prognostic factor for both survival and relapse.

Basic biology

Cell of origin

Ependymomas are believed to arise from radial glial cells. Tumorspheres derived from ependymomas display a radial-glial like phenotype, expressing neuronal stem cell markers CD133 and nestin, as well as radial glial specific markers RC2 and brain lipid binding protein (BLBP/FABP7). Tumorspheres with radial glial characteristics form tumors in orthotopic mouse xenografts, suggesting radial glial as cell of origin for ependymomas.[1][2]

Inheritance

A number of genetic syndromes are associated with the development of ependymoma, including neurofibromatosis type II (NF2), Turcot syndrome B, and MEN1 syndrome. However, gene mutations linked to the familial syndromes are rarely found in sporadic cases of ependymoma.[3] For example, NF2 mutations have rarely been observed in ependymomas and MEN1 mutations have only been found in a small number of cases of ependymoma recurrences.[4][5][6][7]

Oncogenic lesions

ERBB2, ERBB4, and human telomerase reverse transcriptase (TERT) gene expression promote tumor cell proliferation, contributing to aggressive tumor behavior.[8][9][10] High expression of epidermal growth factor receptor (EGFR) correlates with unfavorable outcome.[9] Over-expression of kinetochore proteins and down-regulation of metallothioneins are associated with recurrence in ependymomas.[11] KIT receptor tyrosine kinase and phospho-KIT were found to be present in pediatric ependymomas and may be involved in angiogenesis associated with those tumors.[12]

Chromosomal changes

Comparative genomic hybridization (CGH) experiments have shown pediatric ependymomas possess a number of genomic anomalies not seen in adult ependymomas.[13] In addition, ependymomas from different locations within the central nervous system (spinal, supratentorial, and infratentorial) can be distinguished by their chromosomal, immunohistochemical, and gene expression differences.[13]

Amplification of chromosome 1q and loss of 6q, 17p and 22q are the most common numerical chromosomal changes in pediatric ependymomas.[14][15][16] Gain of chromosome 1q (1q21.1-32.1) is more common in the pediatric population and is associated with tumor recurrence in intracranial ependymomas. Moreover, gain of chromosome 1q25 has been found to independent prognostic value for recurrence-free and overall survival.[9] Loss of 22q has been found in both sporadic and familial cases, supporting the presence of a tumor suppressor gene at this location.[17][18] However, loss of 22q is more common in the adult form than pediatric cases.[14][18][19] As NF2 is located on 22q12.2, it was hypothesized to be involved in the development of ependymoma. Though mutations in NF2 are rarely found in sporadic ependymomas other than the spinal form,[4][20] SCHIP1, a NF2 interacting gene, is significantly down-regulated in pediatric ependymomas, supporting a role for the NF2 pathway in the initiation of ependymomas.[21]

Oncogenes and tumor suppressor genes

A variety of oncogenes and tumor suppressor genes have been found to be mutated or possess altered expression in pediatric ependymomas. KIT receptor tyrosine kinase and phospho-KIT have been suggested to play a role in the development of pediatric ependymomas,[12] NOTCH1 mutations have been found in approximately 8% of pediatric ependymomas,[22] and MEN1 mutations are occasionally found in pediatric ependymomas.[23] MMP2 and MMP14 appear to also play a role in tumor growth and progression in intracranial cases.[24] Two candidate genes, TPR and CHIBBY, have been identified on commonly altered chromosome regions in pediatric ependymomas, chromosomes 1q25 and chromosome 22q12-q13.[25] Expression of two additional candidate genes, S100A6 and S100A4 on chromosome 1q have also been found to correspond to supratentorial tumor development and tumors occurring before the age of 3 years old, though it is unclear exactly what role these genes play in the etiology.[26]

Tumor progression

Ependymomas have been suggested to arise from radial glial cells, suggesting neural stem cell maintenance pathways such as Notch, sonic hedgehog (SHH), and p53 are important for the pathogenesis of ependymomas.[1]

Notch signaling pathway and HOX family of transcription factors are up regulated in supratentorial and spinal ependymomas respectively.[1] Over-expression of Notch ligands, receptors, and target genes (HES1, HEY2, and MYC), as well as down-regulation of Notch repressor (Fbxw7) are found in pediatric ependymoma.[22] Inhibition of Notch pathway impairs tumor growth in vitro.[22] Notch target ErbB2 is up-regulated in most ependymomas, correlating with poor outcome.[8]

While p53 (TP53) mutations are not often observed in pediatric ependymoma,[27] the p53 pathway is suggested to play a role in radiation therapy resistance[28] and tumor progression,[29] possibly via over-expression of MDM2.[30] Further, up-regulation of p73 (TP73), a homolog of p53, and deletion of the p53 pathway gene p14arf/p16/INK4A (CDKN2A) have also been found in pediatric ependymomas.[3]

Over-expression of components of SHH pathway such as GLI1, GLI2, and STK36 implicates deregulation of the SHH pathway in ependymomas.[3] Moreover, over-expression of SHH targets IGFBP2, IGFBP3, and IGFBP5 in ependymoma is also suggestive of a role for SHH and insulin-like growth factor (IGF) signaling in the pathogenesis of pediatric ependymomas.[31]

Rate of progression

Endothelial cell KIT expression was associated with a young age at diagnosis of pilocytic astrocytoma or ependymoma.[12] Telomerase activity is found in childhood ependymoma. In addition, telomerase reactivation and maintenance of telomeres appears to be required for progression. Low expression of nucleolin, an interacting protein of telomerase, was found to be the single most important biological predictor of outcome, where low expression correlates with a more favorable prognosis.[32]

Clinical biology

Presentation

Symptoms present 1–36 months before diagnosis, and can vary depending on age, tumor grade, and location. Increased intracranial pressure can induce vomiting, headache, irritability, lethargy, changes in gait, and in children less than 2, feeding problems, involuntary eye movements, and hydrocephalus are often noticeable. Seizures occur in about 20% of pediatric patients.[33][34] Loss of cognitive function and even sudden death could occur if the tumor is located at a crucial location for CSF flow. Pediatric ependymomas most often occur in the posterior cranial fossa, in contrast with adult ependymomas which usually occur along the spine.[35] Ependymomas present as low-density masses on CT scans, and are hyperintense on T2-weighted MRI images.[36]

Pathology

Significant debate remains over grading of ependymomas,[37] though the WHO 2007 classification lists subependymoma (grade I), myxopapillary ependymoma (grade I), ependymoma (grade II), and anaplastic ependymoma (grade III) as the primary classifications.[38] This classification scheme further designates four subtypes within the ependymoma group. However, there are several recognized subtypes of ependymoma with differing pathologies. These include myxopapillary ependymoma (MEPN) which tend to grow slowly and are restricted to the conus medullaris-cauda equina-filum terminale region of the spinal cord, intracranial, infratentorial (posterior fossa), intracranial supratentorial, and spinal ependymoma, and subependymomas. Reports have shown that location-based classification is most relevant to the molecular characteristics, implicating underlying tissue-specificity effects.[1]

Ependymomas arise from oncogenic events mutating normal ependymal cells into cancerous cells. Recent evidence suggests the primary cells are radial glia. Genetic alterations are fairly heterogeneous among histologically similar ependymoma tumors.[1]

Diagnostic features

Comparative genomic hybridization (CGH) experiments have shown pediatric tumors possess a number of genomic anomalies not seen in adult ependymomas, with a high prevalence of whole chromosome imbalances.[13][39] Epithelial membrane antigen has been shown to help distinguish ependymomas from other pediatric CNS tumors.[40] Neuraxis MR imaging and lumbar CSF cytology evaluation are widely accepted methods for determining tumor dissemination.[41]

Differential diagnoses

Once a tumor is suspected, medulloblastomas, diffuse astrocytomas, pilocytic astrocytomas, and ependymomas remain in the differential diagnosis as posterior fossa tumors. However, only pilocytic astrocytomas and ependymomas stain positively for Galectin-3.[42] The subtype of ependymoma can also be narrowed down by molecular means. For instance, the myxopapillary ependyomas have been found to have higher expression of HOXB5, PLA2G5, and ITIH2.[43] A gene expression profiling experiment has shown that three members of the SOX family of transcription factors also possessed discriminatory power between medulloblastomas and ependymomas.[44] Without histology, it is difficult to differentiate grade II versus grade III anaplastic ependymomas because there are no anatomical differences on magnetic resonance imaging.[45]

Prognostic features

In general, pediatric ependymomas are associated with less favorable prognoses than adult ependymomas, and ependymomas of younger pediatric patients are less favorable than ependymomas of older pediatric patients (reviewed in [35]). Tumors that occur in the posterior fossa have also been shown to have a less favorable prognosis.[46] Expression of TERT in pediatric intracranial ependymomas is correlated with telomerase activity and tumor progression and negatively correlated with survival.[47] The protein nucleolin and expression of MMP2 and MMP14 have been found to inversely correlate with progression free survival in cases of pediatric ependymoma, though RTK-1 family members were not correlated.[24][32] Tumor microinvasion, even in tumors appearing well-demarcated using various imaging modalities, was also found to be inversely associated with|progression-free and overall survival.[24] Some evidence suggests chromosome 6q25.3 deletion may provide additional survival benefit in pediatric ependymomas.[48]

Treatment

Chemotherapy regimens for pediatric ependymomas have produced only modest benefit and degree of resection remains the most conspicuous factor in recurrence and survival.[49][50][51][52][53]

The association of TERT expression with poor outcome in pediatric ependymomas has driven some researchers to suggest that telomerase inhibition may be an effective adjuvant therapy for pediatric ependymomas. Further, data from in vitro experiments using primary tumor isolate cells suggest that inhibition of telomerase activity may inhibit cell proliferation and increase sensitivity of cells to DNA damaging agents,[54] consistent with the observation of high telomerase activity in primary tumors.[32] Additionally, because apurinic/apyrimidinic endonuclease (APE1) has been found to confer radiation resistance in pediatric ependymomas, it has been suggested that inhibitors of Ap endo activity might also restore radiation sensitivity.[55]

Within the infratentorial group of pediatric ependymomas, radiotherapy was found to significantly increase 5-year survival.[56] However, a retrospective review of sterotactic radiosurgery showed it provided only a modest benefit to patients who had previously undergone resection and radiation.[57] Though other supratentorial tumors tend to have a better prognosis, supratentorial anaplastic ependymomas are the most aggressive ependymoma and neither total excision nor postoperative irradiation was found to be effective in preventing early recurrence.[58]

Following resection of infratentorial ependymomas, residual tumor is more likely in lateral versus medial tumors, classified radiologically pre-operatively.[59][60] Specific techniques, such as cerebellomedullary fissure dissection have been proposed to aid in complete resection while avoiding iatrogenic effects in these cases.[60] Surveillance neuroimaging for recurrence provides additional survival to patients over observation alone.[61]

Biochemical markers

hTERT and yH2AX are crucial markers for prognosis and response to therapy. High hTERT and low yH2AX expression is associated with poor response to therapy. Patients with both high or low expression of these markers make up the moderate response groups.[62]

Relapse

The 5-year disease-free survival for age >5 years is 50-60%.[63] Another report found a similar 5-year survival at about 65% with 51% progression-free survival.[64] The 10-year disease-free survival is 40-50%. Younger ages showed lower 5 and 10-year survival rates.[63] A 2006 study that observed 133 patients found 31 (23.3%) had a recurrence of the disease within a five-year period.[62]

Long-term consequences of treatment

Use of telomerase inhibitors such as Imetelstat seem to have very low toxicity compared to other chemotherapy. The only known side effect of most telomerase inhibitors is dose-induced neutropenia.[65] Neuropsychological deficits can result from resection,[66] chemotherapy,[67] and radiation, as well as endocrinopathies.[68] Additionally, an increase in gastrointestinal complications has been observed in survivors of pediatric cancers.[69]

References

  1. 1 2 3 4 5 Taylor, MD; Poppleton, H; Fuller, C; Su, X; Liu, Y; Jensen, P; Magdaleno, S; Dalton, J; et al. (2005). "Radial glia cells are candidate stem cells of ependymoma". Cancer Cell. 8 (4): 323–35. doi:10.1016/j.ccr.2005.09.001. PMID 16226707.
  2. ↑ Hartfuss, E; Galli, R; Heins, N; Götz, M (2001). "Characterization of CNS precursor subtypes and radial glia". Developmental Biology. 229 (1): 15–30. doi:10.1006/dbio.2000.9962. PMID 11133151.
  3. 1 2 3 De Bont, JM; Packer, RJ; Michiels, EM; Den Boer, ML; Pieters, R (2008). "Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective". Neuro-Oncology. 10 (6): 1040–60. doi:10.1215/15228517-2008-059. PMC 2719002. PMID 18676356.
  4. 1 2 Rubio, MP; Correa, KM; Ramesh, V; MacCollin, MM; Jacoby, LB; Von Deimling, A; Gusella, JF; Louis, DN (1994). "Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas". Cancer Research. 54 (1): 45–7. PMID 8261460.
  5. ↑ Birch, BD; Johnson, JP; Parsa, A; Desai, RD; Yoon, JT; Lycette, CA; Li, YM; Bruce, JN (1996). "Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas". Neurosurgery. 39 (1): 135–40. doi:10.1097/00006123-199607000-00026. PMID 8805149.
  6. ↑ Ebert, C; Von Haken, M; Meyer-Puttlitz, B; Wiestler, OD; Reifenberger, G; Pietsch, T; Von Deimling, A (1999). "Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas". The American Journal of Pathology. 155 (2): 627–32. doi:10.1016/S0002-9440(10)65158-9. PMC 1866851. PMID 10433955.
  7. ↑ Buccoliero, AM; Castiglione, F; Degl'innocenti, DR; Sardi, I; Genitori, L; Taddei, GL (2010). "Merlin expression in pediatric anaplastic ependymomas real time PCR study" (PDF). Fetal and Pediatric Pathology. 29 (4): 245–54. doi:10.3109/15513811003789644. hdl:2158/795259. PMID 20594149. S2CID 40842469.
  8. 1 2 Gilbertson, RJ; Bentley, L; Hernan, R; Junttila, TT; Frank, AJ; Haapasalo, H; Connelly, M; Wetmore, C; et al. (2002). "ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease". Clinical Cancer Research. 8 (10): 3054–64. PMID 12374672.
  9. 1 2 3 Mendrzyk, F; Korshunov, A; Benner, A; Toedt, G; Pfister, S; Radlwimmer, B; Lichter, P (2006). "Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma". Clinical Cancer Research. 12 (7 Pt 1): 2070–9. doi:10.1158/1078-0432.CCR-05-2363. PMID 16609018. S2CID 12006455.
  10. ↑ Rushing, EJ; Yashima, K; Brown, DF; White Cl, 3rd; Shay, JW; Risser, RC; Gazdar, AF (1997). "Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas". Journal of Neuropathology and Experimental Neurology. 56 (10): 1142–6. doi:10.1097/00005072-199710000-00008. PMID 9329458. S2CID 36687980.
  11. ↑ Peyre, M; Commo, F; Dantas-Barbosa, C; Andreiuolo, F; Puget, S; Lacroix, L; Drusch, F; Scott, V; et al. (2010). Jones, Chris (ed.). "Portrait of ependymoma recurrence in children: Biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis". PLOS ONE. 5 (9): e12932. Bibcode:2010PLoSO...512932P. doi:10.1371/journal.pone.0012932. PMC 2945762. PMID 20885975.
  12. 1 2 3 Puputti, M; Tynninen, O; Pernilä, P; Salmi, M; Jalkanen, S; Paetau, A; Sihto, H; Joensuu, H (2010). "Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors". Brain Pathology (Zurich, Switzerland). 20 (4): 763–70. doi:10.1111/j.1750-3639.2009.00357.x. PMC 2901521. PMID 20030644.
  13. 1 2 3 Kilday, JP; Rahman, R; Dyer, S; Ridley, L; Lowe, J; Coyle, B; Grundy, R (2009). "Pediatric ependymoma: Biological perspectives". Molecular Cancer Research. 7 (6): 765–86. doi:10.1158/1541-7786.MCR-08-0584. PMID 19531565. S2CID 2409031.
  14. 1 2 Mazewski, C; Soukup, S; Ballard, E; Gotwals, B; Lampkin, B (1999). "Karyotype studies in 18 ependymomas with literature review of 107 cases". Cancer Genetics and Cytogenetics. 113 (1): 1–8. doi:10.1016/S0165-4608(99)00046-1. PMID 10459338.
  15. ↑ Reardon, DA; Entrekin, RE; Sublett, J; Ragsdale, S; Li, H; Boyett, J; Kepner, JL; Look, AT (1999). "Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma". Genes, Chromosomes & Cancer. 24 (3): 230–7. doi:10.1002/(SICI)1098-2264(199903)24:3<230::AID-GCC8>3.0.CO;2-C. PMID 10451703.
  16. ↑ Ward, S; Harding, B; Wilkins, P; Harkness, W; Hayward, R; Darling, JL; Thomas, DG; Warr, T (2001). "Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma". Genes, Chromosomes & Cancer. 32 (1): 59–66. doi:10.1002/gcc.1167. hdl:2436/16712. PMID 11477662. S2CID 10805975.
  17. ↑ Nijssen, PC; Deprez, RH; Tijssen, CC; Hagemeijer, A; Arnoldus, EP; Teepen, JL; Holl, R; Niermeyer, MF (1994). "Familial anaplastic ependymoma: Evidence of loss of chromosome 22 in tumour cells". Journal of Neurology, Neurosurgery, and Psychiatry. 57 (10): 1245–8. doi:10.1136/jnnp.57.10.1245. PMC 485495. PMID 7931388.
  18. 1 2 Von Haken, MS; White, EC; Daneshvar-Shyesther, L; Sih, S; Choi, E; Kalra, R; Cogen, PH (1996). "Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas". Genes, Chromosomes & Cancer. 17 (1): 37–44. doi:10.1002/(SICI)1098-2264(199609)17:1<37::AID-GCC6>3.0.CO;2-3. PMID 8889505.
  19. ↑ Kramer, DL; Parmiter, AH; Rorke, LB; Sutton, LN; Biegel, JA (1998). "Molecular cytogenetic studies of pediatric ependymomas". Journal of Neuro-Oncology. 37 (1): 25–33. doi:10.1023/A:1005925613992. PMID 9525835. S2CID 2339505.
  20. ↑ Slavc, I; MacCollin, MM; Dunn, M; Jones, S; Sutton, L; Gusella, JF; Biegel, JA (1995). "Exon scanning for mutations of the NF2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas". International Journal of Cancer. 64 (4): 243–7. doi:10.1002/ijc.2910640406. PMID 7657387. S2CID 26113908.
  21. ↑ Suarez-Merino, B; Hubank, M; Revesz, T; Harkness, W; Hayward, R; Thompson, D; Darling, JL; Thomas, DG; Warr, TJ (2005). "Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3". Neuro-Oncology. 7 (1): 20–31. doi:10.1215/S1152851704000596). PMC 1871622. PMID 15701279.
  22. 1 2 3 Puget, S; Grill, J; Valent, A; Bieche, I; Dantas-Barbosa, C; Kauffmann, A; Dessen, P; Lacroix, L; et al. (2009). "Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas". Journal of Clinical Oncology. 27 (11): 1884–92. doi:10.1200/JCO.2007.15.4195. PMID 19289631.
  23. ↑ Urioste, M; Martínez-Ramírez, A; Cigudosa, JC; Colmenero, I; Madero, L; Robledo, M; Martínez-Delgado, B; Benítez, J (2002). "Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma". Cancer Genetics and Cytogenetics. 138 (2): 107–10. doi:10.1016/S0165-4608(01)00532-5. PMID 12505253.
  24. 1 2 3 Snuderl, M; Chi, SN; De Santis, SM; Stemmer-Rachamimov, AO; Betensky, RA; De Girolami, U; Kieran, MW (2008). "Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas". Journal of Neuropathology and Experimental Neurology. 67 (9): 911–20. doi:10.1097/NEN.0b013e318184f413. PMC 2686114. PMID 18716553.
  25. ↑ Karakoula, K; Suarez-Merino, B; Ward, S; Phipps, KP; Harkness, W; Hayward, R; Thompson, D; Jacques, TS; et al. (2008). "Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13". Genes, Chromosomes & Cancer. 47 (11): 1005–22. doi:10.1002/gcc.20607. PMID 18663750. S2CID 39179289.
  26. ↑ Rand, V; Prebble, E; Ridley, L; Howard, M; Wei, W; Brundler, MA; Fee, BE; Riggins, GJ; et al. (2008). "Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma". British Journal of Cancer. 99 (7): 1136–43. doi:10.1038/sj.bjc.6604651. PMC 2567087. PMID 18781180.
  27. ↑ Fink, KL; Rushing, EJ; Schold Jr, SC; Nisen, PD (1996). "Infrequency of p53 gene mutations in ependymomas". Journal of Neuro-Oncology. 27 (2): 111–5. doi:10.1007/bf00177473. PMID 8699232. S2CID 35235002.
  28. ↑ Gaspar, N; Grill, J; Geoerger, B; Lellouch-Tubiana, A; Michalowski, MB; Vassal, G (2006). "P53 Pathway dysfunction in primary childhood ependymomas". Pediatric Blood & Cancer. 46 (5): 604–13. doi:10.1002/pbc.20532. PMID 16086408. S2CID 25126455.
  29. ↑ Sharma, MC; Ghara, N; Jain, D; Sarkar, C; Singh, M; Mehta, VS (2009). "A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas". Neuropathology. 29 (2): 148–55. doi:10.1111/j.1440-1789.2008.00962.x. PMID 18721229. S2CID 36816458.
  30. ↑ Suzuki, SO; Iwaki, T (2000). "Amplification and overexpression of mdm2 gene in ependymomas". Modern Pathology. 13 (5): 548–53. doi:10.1038/modpathol.3880095. PMID 10824927. S2CID 23561451.
  31. ↑ De Bont, JM; Van Doorn, J; Reddingius, RE; Graat, GH; Passier, MM; Den Boer, ML; Pieters, R (2008). "Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients". International Journal of Cancer. 123 (3): 594–600. doi:10.1002/ijc.23558. PMID 18478565. S2CID 24781824.
  32. 1 2 3 Ridley, L; Rahman, R; Brundler, MA; Ellison, D; Lowe, J; Robson, K; Prebble, E; Luckett, I; et al. (2008). "Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma". Neuro-Oncology. 10 (5): 675–89. doi:10.1215/15228517-2008-036. PMC 2666244. PMID 18701711.
  33. ↑ Piepmeier, JM (1996). "Tumors and approaches to the lateral ventricles. Introduction and overview". Journal of Neuro-Oncology. 30 (3): 267–74. doi:10.1007/bf00177278. PMID 8943102. S2CID 11019256.
  34. ↑ Shemie, S; Jay, V; Rutka, J; Armstrong, D (1997). "Acute obstructive hydrocephalus and sudden death in children". Annals of Emergency Medicine. 29 (4): 524–8. doi:10.1016/S0196-0644(97)70227-0. PMID 9095015.
  35. 1 2 Tamburrini, G; D'ercole, M; Pettorini, BL; Caldarelli, M; Massimi, L; Di Rocco, C (2009). "Survival following treatment for intracranial ependymoma: A review". Child's Nervous System. 25 (10): 1303–12. doi:10.1007/s00381-009-0874-y. PMID 19387655. S2CID 24939807.
  36. ↑ Peretti-Viton, P; Perez Castillo, AM; Martini, P; Margain, D; Murayama, N (1991). "Supratentorial ependymomas. Neuroradiological study". Journal of Neuroradiology. Journal de Neuroradiologie. 18 (2): 201–9. PMID 1919685.
  37. ↑ Godfraind, C (2009). "Classification and controversies in pathology of ependymomas". Child's Nervous System. 25 (10): 1185–93. doi:10.1007/s00381-008-0804-4. PMID 19212775. S2CID 25100075.
  38. ↑ Louis, DN; Ohgaki, H; Wiestler, OD; Cavenee, WK; Burger, PC; Jouvet, A; Scheithauer, BW; Kleihues, P (2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathologica. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.
  39. ↑ Pezzolo, A; Capra, V; Raso, A; Morandi, F; Parodi, F; Gambini, C; Nozza, P; Giangaspero, F; et al. (2008). "Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma". Cancer Letters. 261 (2): 235–43. doi:10.1016/j.canlet.2007.11.021. PMID 18179864.
  40. ↑ Takei, H; Bhattacharjee, MB; Rivera, A; Dancer, Y; Powell, SZ (2007). "New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors". Archives of Pathology & Laboratory Medicine. 131 (2): 234–41. doi:10.5858/2007-131-234-NIMITE. ISSN 1543-2165. PMID 17284108.
  41. ↑ Terterov, S; Krieger, MD; Bowen, I; McComb, JG (2010). "Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas". Journal of Neurosurgery. Pediatrics. 6 (2): 131–6. doi:10.3171/2010.5.PEDS09333. PMID 20672933. S2CID 32766866.
  42. ↑ Borges, CB; Bernardes, ES; Latorraca, EF; Becker, AP; Neder, L; Chammas, R; Roque-Barreira, MC; Machado, HR; De Oliveira, RS (2011). "Galectin-3 expression: A useful tool in the differential diagnosis of posterior fossa tumors in children". Child's Nervous System. 27 (2): 253–7. doi:10.1007/s00381-010-1262-3. PMID 20711594. S2CID 41243460.
  43. ↑ Barton, VN; Donson, AM; Kleinschmidt-Demasters, BK; Birks, DK; Handler, MH; Foreman, NK (2010). "Unique molecular characteristics of pediatric myxopapillary ependymoma". Brain Pathology (Zurich, Switzerland). 20 (3): 560–70. doi:10.1111/j.1750-3639.2009.00333.x. PMC 2871180. PMID 19793339.
  44. ↑ De Bont, JM; Kros, JM; Passier, MM; Reddingius, RE; Sillevis Smitt, PA; Luider, TM; Den Boer, ML; Pieters, R (2008). "Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis". Neuro-Oncology. 10 (5): 648–60. doi:10.1215/15228517-2008-032. PMC 2666242. PMID 18577562.
  45. ↑ Martínez León, MI; Vidal Denis, M; Weil Lara, B (2011). "Magnetic resonance imaging of infratentorial anaplastic ependymoma in children". Radiología. 54 (1): 59–64. doi:10.1016/j.rx.2011.01.005. PMID 21530988.
  46. ↑ Sala, F; Talacchi, A; Mazza, C; Prisco, R; Ghimenton, C; Bricolo, A (1998). "Prognostic factors in childhood intracranial ependymomas: The role of age and tumor location". Pediatric Neurosurgery. 28 (3): 135–42. doi:10.1159/000028637. PMID 9705591. S2CID 46820616.
  47. ↑ Tabori, U; Ma, J; Carter, M; Zielenska, M; Rutka, J; Bouffet, E; Bartels, U; Malkin, D; Hawkins, C (2006). "Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma". Journal of Clinical Oncology. 24 (10): 1522–8. doi:10.1200/JCO.2005.04.2127. PMID 16575002.
  48. ↑ Monoranu, CM; Huang, B; Zangen, IL; Rutkowski, S; Vince, GH; Gerber, NU; Puppe, B; Roggendorf, W (2008). "Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas". Cancer Genetics and Cytogenetics. 182 (1): 18–26. doi:10.1016/j.cancergencyto.2007.12.008. PMID 18328946.
  49. ↑ Wright, KD; Gajjar, A (2009). "New chemotherapy strategies and biological agents in the treatment of childhood ependymoma". Child's Nervous System. 25 (10): 1275–82. doi:10.1007/s00381-009-0809-7. PMC 2738756. PMID 19212772.
  50. ↑ Shim, KW; Kim, DS; Choi, JU (2009). "The history of ependymoma management". Child's Nervous System. 25 (10): 1167–83. doi:10.1007/s00381-009-0900-0. PMID 19458954. S2CID 1168021.
  51. ↑ Little, AS; Sheean, T; Manoharan, R; Darbar, A; Teo, C (2009). "The management of completely resected childhood intracranial ependymoma: The argument for observation only". Child's Nervous System. 25 (3): 281–4. doi:10.1007/s00381-008-0799-x. PMID 19153750. S2CID 10791698.
  52. ↑ Goldwein, JW; Leahy, JM; Packer, RJ; Sutton, LN; Curran, WJ; Rorke, LB; Schut, L; Littman, PS; D'angio, GJ (1990). "Intracranial ependymomas in children". International Journal of Radiation Oncology, Biology, Physics. 19 (6): 1497–502. doi:10.1016/0360-3016(90)90362-N. PMID 2262372.
  53. ↑ Tihan, T; Zhou, T; Holmes, E; Burger, PC; Ozuysal, S; Rushing, EJ (2008). "The prognostic value of histological grading of posterior fossa ependymomas in children: A Children's Oncology Group study and a review of prognostic factors". Modern Pathology. 21 (2): 165–77. doi:10.1038/modpathol.3800999. PMID 18084249. S2CID 12129583.
  54. ↑ Wong, VC; Morrison, A; Tabori, U; Hawkins, CE (2010). "Telomerase inhibition as a novel therapy for pediatric ependymoma". Brain Pathology (Zurich, Switzerland). 20 (4): 780–6. doi:10.1111/j.1750-3639.2010.00372.x. PMC 8094828. PMID 20184588. S2CID 12167031.
  55. ↑ Bobola, MS; Jankowski, P; Gross, ME; Schwartz, J; Finn, LS; Blank, A; Ellenbogen, RG; Silber, JR (2011). "Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma". International Journal of Cancer. 129 (10): 2370–2379. doi:10.1002/ijc.25900. PMC 3285472. PMID 21207372.
  56. ↑ McGuire, CS; Sainani, KL; Fisher, PG (2009). "Both location and age predict survival in ependymoma: A SEER study". Pediatric Blood & Cancer. 52 (1): 65–9. doi:10.1002/pbc.21806. PMID 19006249. S2CID 39107535.
  57. ↑ Kano, H; Yang, HC; Kondziolka, D; Niranjan, A; Arai, Y; Flickinger, JC; Lunsford, LD (2010). "Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas". Journal of Neurosurgery. Pediatrics. 6 (5): 417–23. doi:10.3171/2010.8.PEDS10252. PMID 21039163. S2CID 21039435.
  58. ↑ Kumar, R; Singhal, N; Jaiswal, SK; Mahapatra, AK (2007). "Recurrence in supratentorial anaplastic ependymoma". Pediatric Neurosurgery. 43 (5): 364–8. doi:10.1159/000106384. PMID 17786000. S2CID 44479846.
  59. ↑ U-King-Im, JM; Taylor, MD; Raybaud, C (2010). "Posterior fossa ependymomas: New radiological classification with surgical correlation". Child's Nervous System. 26 (12): 1765–72. doi:10.1007/s00381-010-1251-6. PMID 20680298. S2CID 36988633.
  60. 1 2 Shimoji, K; Miyajima, M; Karagiozov, K; Yatomi, K; Matsushima, T; Arai, H (2009). "Surgical considerations in fourth ventricular ependymoma with the transcerebellomedullary fissure approach in focus". Child's Nervous System. 25 (10): 1221–8. doi:10.1007/s00381-009-0835-5. PMID 19360422. S2CID 11225552.
  61. ↑ Good, CD; Wade, AM; Hayward, RD; Phipps, KP; Michalski, AJ; Harkness, WF; Chong, WK (2001). "Surveillance neuroimaging in childhood intracranial ependymoma: How effective, how often, and for how long?". Journal of Neurosurgery. 94 (1): 27–32. doi:10.3171/jns.2001.94.1.0027. PMID 11147894.
  62. 1 2 Tabori, U; Wong, V; Ma, J; Shago, M; Alon, N; Rutka, J; Bouffet, E; Bartels, U; et al. (2008). "Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma". British Journal of Cancer. 99 (7): 1129–35. doi:10.1038/sj.bjc.6604652. PMC 2567068. PMID 18797459.
  63. 1 2 Sanford, RA; Gajjar, A (1997). "Ependymomas". Clinical Neurosurgery. 44: 559–70. PMID 10080027.
  64. ↑ Agaoglu, FY; Ayan, I; Dizdar, Y; Kebudi, R; Gorgun, O; Darendeliler, E (2005). "Ependymal tumors in childhood". Pediatric Blood & Cancer. 45 (3): 298–303. doi:10.1002/pbc.20212. PMID 15770637. S2CID 45562929.
  65. ↑ Castelo-Branco, P; Zhang, C; Lipman, T; Fujitani, M; Hansford, L; Clarke, I; Harley, CB; Tressler, R; et al. (2011). "Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition". Clinical Cancer Research. 17 (1): 111–21. doi:10.1158/1078-0432.CCR-10-2075. PMID 21208905. S2CID 727839.
  66. ↑ Levisohn, L; Cronin-Golomb, A; Schmahmann, JD (2000). "Neuropsychological consequences of cerebellar tumour resection in children: Cerebellar cognitive affective syndrome in a paediatric population". Brain. 123 (5): 1041–50. doi:10.1093/brain/123.5.1041. PMID 10775548.
  67. ↑ Winick, N (2011). "Neurocognitive outcome in survivors of pediatric cancer". Current Opinion in Pediatrics. 23 (1): 27–33. doi:10.1097/MOP.0b013e32834255e9. PMID 21157347. S2CID 205834954.
  68. ↑ Mostoufi-Moab, S; Grimberg, A (2010). "Pediatric brain tumor treatment: Growth consequences and their management". Pediatric Endocrinology Reviews. 8 (1): 6–17. PMC 4148717. PMID 21037539.
  69. ↑ Goldsby, R; Chen, Y; Raber, S; Li, L; Diefenbach, K; Shnorhavorian, M; Kadan-Lottick, N; Kastrinos, F; et al. (2011). "Survivors of childhood cancer have increased risk of gastrointestinal complications later in life". Gastroenterology. 140 (5): 1464–71.e1. doi:10.1053/j.gastro.2011.01.049. PMC 3081911. PMID 21315721.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.